Compare LIXT & PURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIXT | PURR |
|---|---|---|
| Founded | 2005 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.4M | 24.9M |
| IPO Year | N/A | N/A |
| Metric | LIXT | PURR |
|---|---|---|
| Price | $3.33 | $4.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.58 |
| AVG Volume (30 Days) | 84.6K | ★ 1.5M |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.64 | $3.01 |
| 52 Week High | $6.26 | $4.65 |
| Indicator | LIXT | PURR |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 67.10 |
| Support Level | $3.04 | $3.26 |
| Resistance Level | $3.53 | $3.90 |
| Average True Range (ATR) | 0.33 | 0.33 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 43.92 | 83.09 |
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.